Semaglutide or tirzepatide for weight management: how do they compare?

Two prescription options often come up in weight-management conversations: injectable semaglutide (Wegovy) and tirzepatide (Zepbound). Semaglutide acts on a hormone pathway called GLP-1; tirzepatide acts on both GLP-1 and GIP pathways. Both are used with nutrition and physical activity for people who meet their approved treatment criteria. The right choice depends on more than a number on the scale, including your medical history, goals, tolerability, and access to treatment. See the current Wegovy label and Zepbound label.

In a 72-week head-to-head trial of adults with obesity but without type 2 diabetes, average body-weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide at the studied injectable doses. That is useful comparative evidence, but it does not predict what any one person will experience or establish which medicine is best for everyone.

Both medicines can cause nausea, vomiting, diarrhea, or constipation, particularly while doses are increased. Their FDA labels also describe important precautions and contraindications, including a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. A clinician should review your health history and other medicines before you start or change treatment.

At Global Medical Excellence, medical weight loss is one of the topics you can discuss with your physician. If you are weighing these options, bring questions about your health goals, past treatments, side effects, and coverage to a visit. Explore our lifestyle medicine services and schedule a conversation if a medical weight-management plan would be useful for you.